Rosuvastatin

Generic Name
Rosuvastatin
Brand Names
Crestor, Ezallor, Roszet
Drug Type
Small Molecule
Chemical Formula
C22H28FN3O6S
CAS Number
287714-41-4
Unique Ingredient Identifier
413KH5ZJ73
Background

Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the e...

Indication

The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.
...

Associated Conditions
Atherosclerosis, Atherosclerotic Cardiovascular Diseases, Cardiovascular Disease (CVD), Cardiovascular Events, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Hypertriglyceridemias, Major Adverse Cardiovascular Events, Mixed Dyslipidemias, Postoperative Thromboembolism, Primary Hypercholesterolemia, Primary Hyperlipidemia
Associated Therapies
Lipid-Lowering Therapy, Primary Prevention of Cardiovascular Diseases
Clinical Trials
Related News

GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF

Phase 3
Completed
Conditions
Heart Failure
Interventions
Drug: n-3 PUFA
Drug: Placebo
Drug: Rosuvastatin
First Posted Date
2006-06-13
Last Posted Date
2015-08-14
Lead Sponsor
Gruppo di Ricerca GISSI
Target Recruit Count
6975
Registration Number
NCT00336336
Locations
🇮🇹

Ospedale Padre Antero Micone, Genova-Sestri Ponente, GE, Italy

🇮🇹

Ospedale Santa Croce, Moncalieri, To, Italy

🇮🇹

INRCA Istituto Cardiovasculop.Senili, Cosenza, CS, Italy

and more 278 locations

Korean Rosuvastatin Effectiveness Study in Nondiabetic Metabolic Syndrome

Phase 4
Completed
Conditions
Hypercholesterolemia
First Posted Date
2006-06-12
Last Posted Date
2007-12-17
Lead Sponsor
AstraZeneca
Target Recruit Count
370
Registration Number
NCT00335699
Locations
🇰🇷

Research Site, Ulsan, Korea, Republic of

Effect of Rosuvastatin on Amnesia and Orientation Through Galveston Outcome Amnesia Test in Moderate Head Injury

Phase 2
Completed
Conditions
Head Injury
Interventions
Drug: rosuvastatin
Drug: Placebo
First Posted Date
2006-05-25
Last Posted Date
2010-06-24
Lead Sponsor
Universidad Autonoma de San Luis Potosí
Target Recruit Count
20
Registration Number
NCT00329758
Locations
🇲🇽

Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosi, Mexico

PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.

Phase 3
Completed
Conditions
Hypercholesterolaemia
First Posted Date
2006-05-24
Last Posted Date
2009-03-16
Lead Sponsor
AstraZeneca
Target Recruit Count
1000
Registration Number
NCT00329173

Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease

Phase 4
Completed
Conditions
Hypercholesteremia
First Posted Date
2006-05-24
Last Posted Date
2011-08-31
Lead Sponsor
AstraZeneca
Target Recruit Count
214
Registration Number
NCT00329160
Locations
🇯🇵

Research Site, Yokohama, Japan

Rosuvastatin and Ischemia Reperfusion

Phase 2
Completed
Conditions
Ischemia
First Posted Date
2006-04-18
Last Posted Date
2008-09-23
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
20
Registration Number
NCT00315510
Locations
🇳🇱

Clinical Research Centre Nijmegen; Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

Phase 2
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Rosuvastatin
Drug: Atorvastatin
First Posted Date
2006-02-27
Last Posted Date
2011-09-01
Lead Sponsor
AstraZeneca
Target Recruit Count
353
Registration Number
NCT00296374
Locations
🇷🇴

Research Site, Timisoara, Romania

🇦🇷

Reasearch Site, La Plata, Argentina

🇭🇺

Research site, Gyula, Hungary

Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

Phase 2
Completed
Conditions
Hyperlipidemia
First Posted Date
2006-02-27
Last Posted Date
2011-06-16
Lead Sponsor
AstraZeneca
Target Recruit Count
237
Registration Number
NCT00296400
Locations
🇿🇦

Research Site, Pretoria, South Africa

Effects in The ApoB/ApoA-I Ratio Using Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

Phase 3
Completed
Conditions
Acute Coronary Syndrome
First Posted Date
2006-02-27
Last Posted Date
2007-12-17
Lead Sponsor
AstraZeneca
Target Recruit Count
1160
Registration Number
NCT00296387
Locations
🇪🇸

Research site, Madrid, Spain

🇹🇳

Research Site, Tunis, Tunisia

Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy?

First Posted Date
2006-02-23
Last Posted Date
2007-04-20
Lead Sponsor
Purdue University
Target Recruit Count
48
Registration Number
NCT00295373
Locations
🇺🇸

Purdue University, West Lafayette, Indiana, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy